- Price
- $6.20
- Day
- +7.27%
- Mkt Cap
- $1.98B
- 52W Range
- $2.63 – $7.30
- Volume
- 2.09M
- Beta
- 1.16
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
DALLAS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2026, and host a corporate update conference call and webcast on Tuesday, August 11, 2026, at 4:30 PM Eastern Time.
Read full article
CAMBRIDGE, Mass. and DALLAS and TAMPA, Fla.
Read full article